Platinum-sensitive recurrent ovarian cancer
Clinical trials for Platinum-sensitive recurrent ovarian cancer explained in plain language.
Never miss a new study
Get alerted when new Platinum-sensitive recurrent ovarian cancer trials appear
Sign up with your email to follow new studies for Platinum-sensitive recurrent ovarian cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…
Matched conditions: PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis trial tests a new experimental drug called CPI-0209 (Tulmimetostat) combined with the chemotherapy drug carboplatin in women whose ovarian cancer has returned but still responds to platinum-based treatments. The study aims to find the safest dose of CPI-0209 when given with …
Matched conditions: PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
Phase 1 • Sponsor: Lan Coffman • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC